Pulmonary Biologics
Stabilized Proteins for Nebulization
Pre-clinicalActive
Key Facts
About Aperiam Bio
Aperiam Bio is a private, preclinical-stage biotech founded in 2021, leveraging a novel AI/computer vision platform for protein engineering. The company emerged from stealth with $9 million in funding and holds a patent for its core technology. Its business model is a hybrid platform/partnership approach, delivering enhanced proteins for partners in cosmetics, technical reagents, and therapeutics, with an initial focus on pulmonary biologics.
View full company profile